Immune Therapeutics, Inc. (IMUN) Granted Approval for Lodonal™ in Nigeria
Earlier today, Immune Therapeutics, Inc. (OTCQB: IMUN) announced that Nigeria’s National Agency for Food and Drug Administration and Control (NAFDAC) has approved the company’s patented Lodonal™ as an over-the-counter, non-toxic adjunct therapy in the treatment of HIV/AIDS. With this approval, IMUN’s distribution partners, AHAR Pharma and GB Pharma Holdings, will now be able to launch nationwide marketing and sales programs for the breakthrough immunotherapy, creating a new revenue stream for IMUN and contributing to health security in Nigeria. “Receiving approval of our affordable non-toxic immunodeficiency treatment Lodonal is a significant company milestone,” Noreen Griffin, chief executive officer of IMUN, stated…